Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Dec 5, 2019

(R) Cantargia selects CAN10 as development project in systemic sclerosis and myocarditis

Dec 2, 2019

(R) Cantargia reports positive interim data from ongoing phase IIa combination study with antibody CAN04

Nov 25, 2019

(R) Cantargia AB: Nomination Committee appointed ahead of 2020 Annual General Meeting

Nov 18, 2019

(R) Cantargia presents novel preclinical data on antibody CAN04 at PEGS Europe conference

Nov 15, 2019

(R) Cantargia advance antibody CAN04 development after positive pre-IND meeting

Nov 15, 2019

(R) Cantargia publishes interim report for third quarter 2019

Oct 10, 2019

(R) Cantargia reports filing of opposition against Cantargia patent in Europe

Sep 4, 2019

(R) Cantargia submits request for pre-IND meeting on CAN04 with US FDA

Aug 23, 2019

(R) Cantargia announce positive preclinical data on CAN04 in bladder cancer

Aug 23, 2019

(R) Cantargia announce positive preclinical data on CAN04 in bladder cancer

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye